Domain-trained AI bot, Allie, is claimed to have scored 678 out of 720 in the NEET 2025 medical entrance examination, with an accuracy of 98.84%. Developed by Allen Career Institute’s digital arm, Allen Online, the bot is touted as a curriculum-aligned academic companion, specifically built for the rigours of Indian competitive exams.
“What makes Allie uniquely effective is how it understands both the question and the context—whether it’s a biology diagram, a tricky physics problem, or a concept from the NCERT syllabus,” a statement released by the company stated. It added that, unlike traditional large language models (LLMs) that rely on a single model, Allie uses a dynamic routing system to select the most suitable LLM model based on a student’s query.
Allen Online CEO Abha Maheshwari claimed that with 98.84% accuracy, Allie has outperformed bots developed by several leading AI and Indian education companies, which typically show accuracy levels between 87% and 94%.
Allie is equipped with a vision-enabled engine to handle diagrams, and complex problems are broken down step by step before a response is generated, the company explained.
“Allie doesn’t attempt a question unless it’s certain of delivering a high-quality answer,” the statement said, adding that the score was achieved independently, without any human intervention.
The company also claimed that the architecture has helped reduce doubt-resolution turnaround time from 113 hours to just five hours over the past 12 months, during which the bot answered over five lakh student queries.
Allen Career Institute CEO Nitin Kukreja said, “This NEET result is a proud milestone, and we’re committed to pushing boundaries—continuously enhancing Allie’s accuracy, depth, and reliability—so students always get the best possible support in their academic journey.”
Allie’s performance results were generated within hours of the NEET exam held on May 4, before answer keys or solutions were widely available on public platforms, the company added.
Your reaction
Discussion
What's your take on this story?
No comments yet — be the first to share your view.